This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arnold M. Moses, MD; Douglas D. Notman, MD

Arch Intern Med. 1982;142(1):128-129.

Abstract
• Secondary hyperparathyroidism developed on two separate occasions in a patient taking an oral contraceptive (OC) in a mixture of norethindrone and mestranol (Ortho-Novum 1/80). The probable cause of this condition is an estrogenic inhibition of the calcium mobilizing effect of parathyroid hormone (PTH) or vitamin D. The possible consequences of OC therapy in this patient and patients like her include those of milk hypocalcemia, moderate hypophosphatemia, or the neurotoxic actions of excessive levels of circulating PTH. One should also consider the possible role of OC therapy in patients with unexplained parathyroid hyperplasia and with tertiary hyperparathyroidism.

(Arch Intern Med 1982;142:128-129)

Author Affiliations
From the Department of Medicine, State University of New York Upstate Medical Center, and the Veterans Administration Medical Center, Syracuse.

Footnotes
Accepted for publication Sept 8, 1980.

Reprint requests to State University Hospital, 750 E Adams St, Syracuse, NY 13210 (Dr Moses).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?